Homeostasis

Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States

Retrieved on: 
Monday, June 5, 2023
Other Retail, Health, Retail, Optical, Specialty, Contact, Prevalence, Sihi, Probal Dasgupta, Tears, OH, Presbyopia, Ageing, Ophthalmology, Homeostasis, Science, Breathability, Bausch & Lomb, NYSE, Patient, Bowling Green, Telescopic sight

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Bausch + Lomb INFUSE® Multifocal silicone hydrogel (SiHy) daily disposable contact lenses.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Bausch + Lomb INFUSE® Multifocal silicone hydrogel (SiHy) daily disposable contact lenses.
  • Our Bausch + Lomb INFUSE Multifocal SiHy contact lenses were designed to directly address the common problems that they experience with multifocal contact lenses, such as contact lens dryness, which nearly 70% of multifocal contact lens wearers report experiencing during lens wear,"1† said Yang Yang, senior vice president, Vision Care, Bausch + Lomb.
  • "Bausch + Lomb INFUSE Multifocal contact lenses demonstrate consistent focusing power in each zone of vision, help ensure a smooth, wettable surface for patient comfort and are easy to fit."
  • In addition, eye care practitioners and contact lens wearers are encouraged to use Bausch + Lomb’s complementary contact lens recycling program to properly recycle their used contact lens materials, including Bausch + Lomb INFUSE Multifocal contact lenses, blister packs and top foils.

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Retrieved on: 
Thursday, May 25, 2023
Medical school, PRS, Korea University, Enzyme, Homeostasis, Molecular medicine, Yonsei University, EMBO, Science Citation Index Expanded, KDDF, Patient, EMBO Molecular Medicine, SCIE, School, Medicine, Pharmacy school, Drug discovery, IPF, Idiopathic pulmonary fibrosis, Safety, Pharmaceutical industry, Pharmacy, Fibrosis, Daewoong Pharmaceutical

SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.

Key Points: 
  • SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.
  • EMBO Molecular Medicine is a SCIE (Science Citation Index Expanded) journal.
  • EMBO is a world-renowned journal with an impact factor 14.005, has a ranking of top 5%.
  • Therefore, Bersiporocin can bring antifibrotic effect through reduced enzymatic activity while still maintaining its critical function in homeostasis.

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Retrieved on: 
Thursday, May 25, 2023
Medical school, PRS, Korea University, Enzyme, Homeostasis, Molecular medicine, Yonsei University, EMBO, Science Citation Index Expanded, KDDF, Patient, EMBO Molecular Medicine, SCIE, School, Medicine, Pharmacy school, Drug discovery, IPF, Idiopathic pulmonary fibrosis, Safety, Pharmaceutical industry, Pharmacy, Fibrosis, Daewoong Pharmaceutical

SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.

Key Points: 
  • SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.
  • EMBO Molecular Medicine is a SCIE (Science Citation Index Expanded) journal.
  • EMBO is a world-renowned journal with an impact factor 14.005, has a ranking of top 5%.
  • Therefore, Bersiporocin can bring antifibrotic effect through reduced enzymatic activity while still maintaining its critical function in homeostasis.

AMERICAN SKIN ASSOCIATION ANNOUNCES 2023 RESEARCH ACHIEVEMENT AWARDS

Retrieved on: 
Wednesday, May 17, 2023
ASA, AWARD, Oregon Health and Science University Center for Women's Health, ISID, Skin cancer, Public policy, Atopic dermatitis, Research, Keio University, Inflammation, Doctor of Philosophy, Autoimmunity, Homeostasis, Peripheral tolerance, Psoriasis, Oregon Health & Science University, Professor, Pemphigus, International Society for Bipolar Disorders, Melanoma, Allergy, GEORGE, Ponce Health Sciences University, Vitiligo, Skin, Medical device, Dermatology, MD

NEW YORK, May 17, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan.

Key Points: 
  • MASAYUKI AMAGAI, MD, PhD 2023 RECIPIENT OF GEORGE W. HAMBRICK AWARD
    NEW YORK, May 17, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan.
  • "ASA is honored to recognize Dr. Hanifin and Dr. Amagai and all the 2023 Research Achievement Award recipients for their tireless efforts in the field of dermatology.
  • Dr. Amagai's clinical and research interests center on autoimmune and allergic skin diseases, skin barrier, and skin immunology.
  • ASA's Research Achievement Awards were instituted in 1989 to help identify established scientists in investigative dermatology and cutaneous biology.

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Retrieved on: 
Thursday, May 11, 2023
Epilepsy, KV7, Seizure, Neuron, Therapy, MES, Eurosport 1, HERG, G&A, Therapeutic Targets Database, CNS, Homeostasis, Research and development, Patient, Administration, Central nervous system disease, R, Research, SCI, Chronic pain, Psychiatry, IND, Conference, Vaccine, Pharmaceutical industry, Cryptocurrency

SEATTLE and CAMBRIDGE, United Kingdom, May 11, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • “We were excited to share our initial preclinical data from ETX-123, our lead candidate in the Kv7 program, during the first quarter,” said Andrew Levin, M.D., Ph.D., executive chairman of Eliem Therapeutics.
  • Further screens also confirmed an encouraging broad selectivity profile, including no GABAA, hERG or other off-target activities at anticonvulsant doses.
  • Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Seismic Therapeutic Announces Presentation of Preclinical Data for Immunoglobin Sculpting Enzyme and Dual-Cell Bidirectional Antibody Programs at IMMUNOLOGY 2023

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Pharmaceutical, Health, Detail, Enzyme, Myasthenia gravis, Inflammation, Multiple sclerosis, Lupus, Doctor of Philosophy, Homeostasis, APC, Journal, Mechanism, Chronic inflammatory demyelinating polyneuropathy, MD, Machine learning, IMPACT, Immunoglobulin G, DCB, AAI, Entrepreneurship, Poster, IG, Standard of care, Rheumatoid arthritis, Vaccine, Seismology, Autoimmunity, Immunology

Enzymes that specifically cleave antibodies may eliminate circulating and immune-complexed Ig, as well as cell surface B cell receptors, thereby modulating Ig-mediated autoimmunity and inflammation.

Key Points: 
  • Enzymes that specifically cleave antibodies may eliminate circulating and immune-complexed Ig, as well as cell surface B cell receptors, thereby modulating Ig-mediated autoimmunity and inflammation.
  • Seismic’s DcB antibody approach targets dysregulated cell-mediated immunity by optimally engaging both T cells and antigen presenting cells (APCs), such as B cells to restore homeostasis.
  • “Our lead Ig sculpting program, a pan-IgG protease, is suitable for the treatment of acute and chronic autoantibody mediated diseases.
  • We are also applying our insights to design additional Ig sculpting enzymes that are selective for IgG subclasses and other Ig isotypes.

Thai Leaf aims for a breakthrough in Thailand’s healthcare industry with its high-quality CBD oil and CBD infused products.

Retrieved on: 
Tuesday, May 9, 2023
GMP, Cannabinoid, Crystallization, Seed, ECS, Distillation, Sleep, New product development, Research, Finance, Inflammation, Appetite, Homeostasis, Science, Hemp, Plant, Nervous system, Cannabis, Growth, Human body, Kingdom, Health, THC, Biomass, Cornell University, Textile, News, Drug, Tea, Security (finance), ASEAN, CBD

Simply put, hemp is known for health as opposed to marijuana which is used for recreational purposes.

Key Points: 
  • Simply put, hemp is known for health as opposed to marijuana which is used for recreational purposes.
  • With the founders' extensive background and experience in both the agricultural and pharmaceutical industry, Thai Leaf's end-game is in pharmaceutical CBD products.
  • The Thai CBD market is currently worth THB 7 billion, and forecasted to grow to THB 50 billion within the next three years.
  • Thai Leaf is the first generation company to be licensed in Thailand for hemp derived CBD.

Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans

Retrieved on: 
Thursday, April 27, 2023
Overload, Heart, Patent, Metal, Gian Maria Annovi, United States Patent and Trademark Office, Cancer, Brain, IP, DSM-IV codes, Homeostasis, Messenger, Lung, Protein, Superoxide dismutase, Iron, Aconitase, Kidney, Liver, APP, NYSE, TSE, Pharmaceutical industry, Dietary supplement, Vaccine

U.S. Patent 11,596,621 B2 is titled, “Prevention or Treatment of Disease States Due to Metal Dis-homeostasis Via Administration of Posiphen [buntanetap] to Healthy or Sick Humans” and was issued on March 7, 2023.

Key Points: 
  • U.S. Patent 11,596,621 B2 is titled, “Prevention or Treatment of Disease States Due to Metal Dis-homeostasis Via Administration of Posiphen [buntanetap] to Healthy or Sick Humans” and was issued on March 7, 2023.
  • The patent is expected to confer protection for use of buntanetap and its related analogue molecules for the prevention and treatment of various neurodegenerative diseases associated with metal dis-homeostasis out to early 2040.
  • The ‘621 patent covers the use of buntanetap for maintaining or restoring heavy metal homeostasis as a method of prevention in healthy humans or as a method of treatment in sick humans.
  • Annovis Bio has patents that cover a wide range of chronic neurodegenerative as well as acute neurodegenerative diseases.

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

Retrieved on: 
Monday, April 17, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Clostridioides difficile infection, LSE, JAMA, CDI, Mayo Clinic, Clostridioides, PureTech Health, Definition, Inflammation, Biomarker, European Congress of Ethnic Religions, Homeostasis, Microbiota, American Medical Association, Journal, ECCMID, User experience, Patient, Division, Risk, Hepatology, Variometer, Biology, Growth, Recurrence, Clinical professor, PRTC, Safety, Pharmaceutical industry, Dentistry, Vedanta, Gastroenterology

The study data confirmed that VE303 prevented recurrent Clostridioides difficile infection (CDI) compared with placebo in the study population.

Key Points: 
  • The study data confirmed that VE303 prevented recurrent Clostridioides difficile infection (CDI) compared with placebo in the study population.
  • The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.
  • The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.
  • This analysis demonstrates the possibility that VE303 may provide benefit beyond microbiome restoration in patients with CDI, by limiting pathological inflammation.

Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

Retrieved on: 
Monday, April 17, 2023
Health, Clinical Trials, General Health, Research, Pharmaceutical, Science, Clostridioides difficile infection, JAMA, CDI, Mayo Clinic, Clostridioides, Definition, Inflammation, Biomarker, European Congress of Ethnic Religions, Homeostasis, Microbiota, American Medical Association, Journal, ECCMID, User experience, Patient, Division, Risk, Hepatology, Variometer, Biology, Growth, Recurrence, Clinical professor, Safety, Pharmaceutical industry, Vaccine, Vedanta, Gastroenterology

The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.

Key Points: 
  • The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.
  • Colonization dynamics is analogous to traditional drug pharmacokinetics and refers to the growth and persistence over time of bacterial strain populations in the human gut.
  • “First-generation microbiome approaches use fecal donor material of variable composition, resulting in inconsistent efficacy outcomes across different clinical studies.
  • This analysis demonstrates the possibility that VE303 may provide benefit beyond microbiome restoration in patients with CDI, by limiting pathological inflammation.